Lv2
148 积分 2023-09-07 加入
Considerations on Interim Evaluation of OS in Pivotal Oncology Trials
3个月前
已完结
Robust Design and Analysis of Clinical Trials With Nonproportional Hazards: A Straw Man Guidance From a Cross-Pharma Working Group
3个月前
已完结
Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group
3个月前
已关闭
Critical review of oncology clinical trial design under non-proportional hazards
4个月前
已完结
Statistical considerations for evaluating treatment effect under various non-proportional hazard scenarios
4个月前
已完结
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial
4个月前
已完结
Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study
6个月前
已完结
M-DODII: Bayesian dose optimization design for randomized phase II study with multiple indications
7个月前
已完结
Conditional and Unconditional Treatment Effects in Randomized Clinical Trials: Estimands, Estimation, and Interpretation
10个月前
已完结
皖公网安备34019202002308
